Erlotinib

Erlotinib is an oral medication used in the treatment of specific types of cancer, primarily non-small cell lung cancer (NSCLC) and pancreatic cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors, specifically targeting the epidermal growth factor receptor (EGFR).
The primary function of erlotinib is to block the signaling pathway that promotes cancer cell growth, ultimately leading to cancer cell death. By inhibiting the EGFR, erlotinib can prevent cancer cells from receiving signals to multiply and spread.
Erlotinib is usually prescribed to patients with advanced stages of cancer or when other treatment options have proven to be ineffective. This medication is not used as a primary treatment for early-stage cancers, but rather in situations where the disease has progressed despite initial therapies.
The administration of erlotinib is typically prescribed in a dose-specific regimen, determined by the patient’s condition and medical history. It is essential for patients to follow the prescribed schedule closely and report any side effects to their healthcare provider. Common side effects include skin rash, diarrhea, and mouth sores, but these are generally manageable with the support of healthcare professionals.